NDA 204153 · Bausch
Luzu
Luliconazole · Topical · Azole Antifungal
NovelLast checked: Nov 20, 2026Latest source record: Feb 20, 2018 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2013
Nov 14, 2013
Approved uses
3
Original approval plus efficacy supplements
Registered trials
11
1 Phase 3, 1 recruiting
FAERS reports
176
131 serious, 15 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Apr 30, 2020.
Luliconazole Cream, 1% is indicated for the topical treatment of interdigital tinea pedis, tinea cruris, and tinea corporis caused by the organisms Trichophyton rubrum and Epidermophyton floccosum . Luliconazole Cream, 1% is an azole antifungal indicated for the topical treatment of interdigital tinea pedis, tinea cruris, and tinea corporis caused by the organisms Trichophyton rubrum and Epidermophyton floccosum. ( 1 )
Mechanism: Luliconazole Cream, 1% is an azole antifungal [see Microbiology ( 12.4 )]. Mechanism of Action Luliconazole is an antifungal that belongs to the azole class. Although the exact mechanism of action against dermatophytes is unknown, luliconazole appears to inhibit ergosterol synthesis by inhibiting the enzyme lanosterol demethylase. Inhibition of this enzyme’s activity by azoles results in decreased amounts of ergosterol, a constituent of fungal cell membranes, and a corresponding accumulation of lanosterol.
Therapeutic areas: Infectious disease and vaccines
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Feb 20, 2018 Supplement 4 · Efficacy LabelLetterPediatric CDTL Review
- Feb 20, 2018 Supplement 5 · Efficacy LabelLetterPediatric CDTL Review
- Nov 14, 2013 Original approval · Type 1 - New Molecular Entity NovelReviewLabelSummary Review
1 products under this application
- LUZU · LULICONAZOLE 1% · CREAM, TOPICAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Luliconazole" as an intervention, any sponsor and status, largest first.
- Safety and Efficacy of Luliconazole Solution, 10% in Subjects With Mild to Moderate OnychomycosisPivotal-lookingCompleted
Topica PharmaceuticalsIndustry
NCT01431820 · 334 participants · Start May 2012 · Primary completion Jun 2014
Drug: Luliconazole Solution, 10%; Vehicle Solution · For: Distal and Lateral Subungual Onychomycosis
Sites: Phoenix, Arizona; Los Angeles, California; San Diego, California · 28 sites in all
- Safety and Efficacy Study of SKX-16 in Participants With Mild to Moderate Distal Subungual OnychomycosisPivotal-lookingNot yet recruiting
SATO Pharmaceutical Co., Ltd.Industry
NCT07929844 · 204 participants (planned) · Start Nov 24, 2026 · Primary completion Sep 23, 2028
Drug: SKX-16 (Luliconazole 10% Solution); Vehicle solution · For: Onychomycosis of Toenails
Sites: Los Angeles, California; San Francisco, California; Miami, Florida · 6 sites in all
- Comparative Efficacy of Luliconazole and Bifonazole Combined With Itraconazole in DermatophytosisPivotal-lookingNot yet recruiting
University of FaisalabadAcademic, hospital or other
NCT07920354 · 182 participants (planned) · Start Dec 1, 2026 · Primary completion Jul 2027
Drug: Itraconazole; Luliconazole Cream 1% and 1 more · For: Tinea Corporis; Tinea Cruris; Tinea Faciei
Sites: Faisalabad, Pakistan · 2 sites in all
- Multicenter Study of the Efficacy and Safety of Luliconazole Cream in Tinea Pedis (Athlete's Foot)Pivotal-lookingCompleted
Tinea PharmaceuticalsIndustry
NCT00869336 · 147 participants · Start Mar 2009 · Primary completion Sep 2009
Drug: Luliconazole Cream 1% - 2 wks; Placebo Comparator -2 wks and 2 more · For: Tinea Pedis
Sites: Fridley, Minnesota; Portland, Oregon; Austin, Texas · 4 sites in all
- Topical Lactoferrin and Luliconazole, Alone or in Combination, for Tinea CorporisPivotal-lookingRecruiting
Kafrelsheikh UniversityAcademic, hospital or other
NCT07937020 · 100 participants (planned) · Start Sep 1, 2026 · Primary completion Jan 2027
Drug: Lactoferrin 2% Cream; Luliconazole 1% Cream and 2 more · For: Tinea Corporis
Sites: Kafr ash Shaykh, Egypt
- Comparison of the Efficacy of Topical Luliconazole 2% Cream vs Topical Ketoconazole 1% Cream in the Treatment of Pityriasis Versicolor.Not yet recruiting
PAEC General Hospital, IslamabadAcademic, hospital or other
NCT07333170 · 86 participants (planned) · Start Feb 2026 · Primary completion Jul 2026
Drug: Luliconazole Cream 1%; Topical ketoconazole 2% cream · For: Pityriasis Versicolor
Bausch Health Americas, Inc.Industry
NCT02767947 · 75 participants · Start Feb 8, 2016 · Primary completion Jun 29, 2016
Drug: Luliconazole Cream 1%; Vehicle Cream · For: Tinea Corporis
Sites: San Cristobal, Dominican Republic; Santo Domingo, Dominican Republic; San Pedro Sula, Honduras
Bausch Health Americas, Inc.Industry
NCT02767271 · 30 participants · Start Dec 2, 2015 · Primary completion Apr 27, 2016
Drug: Luliconazole Cream 1% · For: Tinea Pedis; Tinea Cruris
Sites: Santo Domingo, Dominican Republic; San Pedro Sula, Honduras
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective12
- hepatic function abnormal9
- nausea9
- constipation8
- pyrexia8
- decreased appetite7
- off label use7
- diarrhoea6
- pneumonia6
- anaemia5
- anxiety5
- erythema5
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2008 | 1 |
| 2010 | 2 |
| 2012 | 5 |
| 2013 | 2 |
| 2014 | 6 |
| 2015 | 10 |
| 2016 | 26 |
| 2017 | 6 |
| 2018 | 13 |
| 2019 | 12 |
| 2020 | 4 |
| 2021 | 11 |
| 2022 | 21 |
| 2023 | 14 |
| 2024 | 15 |
| 2025 | 18 |
| 2026 | 10 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Luzu (Luliconazole)
2024 spending
$6K
Beneficiaries
n/a
13 claims
Per beneficiary
n/a
$8.03 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $47,412 |
| 2021 | $40,721 |
| 2022 | $26,500 |
| 2023 | $18,074 |
| 2024 | $6,262 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Efficacy and tolerability of luliconazole cream 1% for dermatophytoses: a meta-analysis.
Feng X, Xie J, Zhuang K, et al. · J Dermatol 2014 · Meta-Analysis
- Topical and device-based treatments for fungal infections of the toenails.
Foley K, Gupta AK, Versteeg S, et al. · Cochrane Database Syst Rev 2020 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Luliconazole for the treatment of interdigital tinea pedis: A double-blind, vehicle-controlled study.
Jarratt M, Jones T, Kempers S, et al. · Cutis 2013 · Comparative Study, Randomized Controlled Trial
- Efficacy Evaluation of Luliconazole-Loaded Nanostructured Lipid Carriers in Treatment-Resistant Dermatophytosis: A Randomized Clinical Trial.
Barogh RE, Jeddi SA, Rokni GR, et al. · Mycoses 2026 · Randomized Controlled Trial
- Efficacy and safety of luliconazole 5% nail solution for the treatment of onychomycosis: A multicenter, double-blind, randomized phase III study.
Watanabe S, Kishida H, Okubo A · J Dermatol 2017 · Clinical Trial, Phase III, Multicenter Study
- The effects of CO2 laser and topical agent combination therapy for onychomycosis: A meta-analysis.
Han Y, Wang Y, Zhang XR, et al. · Dermatol Ther 2021 · Meta-Analysis, Review
Sponsor: Bausch
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.